BioSpace News Archive

Connolly, who has more than 20 years of experience in immunotherapy, will design the Institute’s overall research strategy and forge new partnerships between the institute and the industry.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 27, 2020.

This morning, AstraZeneca announced the approval of the triple-therapy Breztri Aerosphere as a maintenance treatment for COPD.

The company posted Phase II data that showed its experimental asset fosmanogepix demonstrated a treatment success rate of 80%.

A U.S. Patent and Trademark Office administrative court rejected Moderna’s arguments that Arbutus’s ‘069 patent should be revoked because it “described obvious concepts.”

According to research from the University of New Hampshire (UNH), new pathways have been identified in an RNA-based virus where inhibitors can potentially unbind. This may be critical to understanding how inhibitors react within the body, and eventually lead to the development of more effective drugs.

It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.

The U.S. Food and Drug Administration (FDA) approved Kite Pharma’s Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). Kite is a Gilead Science company.

The Prescription Drug User Fee Act (PDUFA) was first passed into law by the U.S. Congress in 1992.

EpimAb Biotherapeutics announced the appointment of Professor Mark Smyth to the company’s Scientific Advisory Board. Currently a Senior Scientist and the Immunology Department Coordinator at QIMR Berghofer Medical Research Institute, Professor Smyth brings over 20 years of immuno-oncology expertise and research experience to the Scientific Advisory Board.